Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter Double-Blind Placebo-Controlled Study of LY2140023 in Schizophrenia
KCT0000980Phase 2
Key facts
- Status
- Withdrawn
- Start
- Oct 2011
- Countries
- 1
- Sponsor
- Eli Lilly and Company
- Modality
- Small Molecules
- Conditions
- schizophrenia
01
Overview
Phase 2, randomised, double-blind trial of pomaglumetad methionil in schizophrenia (4 arms), sponsored by Eli Lilly and Company. Planned start Oct 2011; status: withdrawn.
02
Design
4 arms- Study design
- RandomizedDouble-blind
LY2140023 low dose
Patients receive a low dose of LY2140023 in double-blind fashion.
LY2140023 medium dose
Patients receive a medium dose of LY2140023 in double-blind fashion.
LY2140023 high dose
Patients receive a high dose of LY2140023 in double-blind fashion.
Placebo
Patients receive placebo in double-blind fashion as the control arm.
03
Who it enrols
Adult patients with a primary diagnosis of schizophrenia according to DSM-IV-TR; healthy volunteers are not included.
Beyond the preview
Go deeper on KCT0000980.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000980.